SMMT Summit Therapeutics Inc.
As of 3:59 PM ET
- SMMT
Loading chart…
- Open
- $10.24
- Previous close
- $10.57
- Day range
- 9.90 – 10.60
- 52-week range
- 9.90 – 29.23
- Volume
- 331.7K
- Avg volume (3M)
- 6.6M
- Market cap
- $8.4B
- P/E (TTM)
- 25.02
- EPS (TTM)
- −$1.06
- Beta
- −1.52
- Dividend yield
- 0.00%
- Next earnings
- Feb 17, 2027(estimated from past report dates; not yet confirmed by the company)
- Ex-dividend
- —
- Sector
- Healthcare
About Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs. Summit Therapeutics Inc. centers its current portfolio on oncology, with ivonescimab as its lead investigational asset, a bispecific antibody designed to combine immune checkpoint blockade with anti-angiogenic activity. The company is advancing ivonescimab in multiple late-stage clinical programs for non-small cell lung cancer and colorectal cancer, often in combination with chemotherapy. Summit Therapeutics Inc. also maintains an anti-infectives program, including ridinilazole, an oral antibiotic candidate studied for Clostridioides difficile infection. Through these product and development efforts, Summit Therapeutics Inc. plays a role in precision medicine across cancer and infectious disease, with a focus on therapies intended to address difficult-to-treat conditions.
Next report: Wed, Feb 17, 2027(estimated from past report dates; not yet confirmed by the company)
| Quarter | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Nov 4, 2026(after close) | −$0.21 | −$0.19 | −9.5% |
| Jul 23, 2026(after close) | −$0.21 | −$0.21 | 0.0% |
| Jul 14, 2026(after close) | $0.09 | $0.13 | +44.4% |
| Apr 30, 2026(after close) | −$0.21 | −$0.18 | −14.3% |
SMMT doesn’t pay a dividend.
SMMT news and filings
Loading filings…
Filings from SEC EDGAR.